APPRECIATE (Apremilast Clinical Treatment Experience in Psoriasis): A Multi-center, Retrospective Observational Study of Real-World Experience of Psoriasis Patients Treated With Apremilast in Clinical Dermatology Practice

Trial Profile

APPRECIATE (Apremilast Clinical Treatment Experience in Psoriasis): A Multi-center, Retrospective Observational Study of Real-World Experience of Psoriasis Patients Treated With Apremilast in Clinical Dermatology Practice

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Apremilast (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Acronyms APPRECIATE
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 23 Aug 2017 Planned number of patients changed from 475 to 515.
    • 23 Aug 2017 Planned End Date changed from 1 May 2017 to 28 Feb 2018.
    • 23 Aug 2017 Planned primary completion date changed from 1 May 2017 to 28 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top